Benzinga | Apr 20, 2021 07:38AM EDT

Palatin Announces Two Presentations At 2021 Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting May 1-7

Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced two presentations of the Company's melanocortin platform, including PL9643 in dry eye disease, at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting, being held virtually May 1-7, 2021.

The presentations highlight the positive clinical data from the Phase 2 clinical study in dry eye disease patients, and the possible utility of melanocortins in the treatment of inflammation and, specifically, ocular inflammation.

"Palatin is excited to present two examples of the significant utility of melanocortins in the treatment for inflammatory conditions. The eye, as well as the gut and kidney, offer a unique environment where melanocortin agonism promotes resolution of inflammation," said Carl Spana, Ph.D., President and CEO of Palatin. "ARVO is the premier global eye and vision forum. We are pleased to showcase Palatin's expertise with melanocortin peptides and how they may provide a safe, well-tolerated, and effective treatment path for inflammatory conditions in the eye."

The presentation details:

Date: May 1, 2021

Time: 3:15 pm to 4:45 pm Eastern Time

Session Title: Dry eye clinical treatments

Format: Podium Presentation

Presenter: Kenneth Kenyon, MD, treating ophthalmologist and primary investigator

Title: "Efficacy and Safety of the Melanocortin Agonist PL9643 in a Phase 2 Study of Subjects with Dry Eye Disease"

Date: May 6, 2021

Time: 11:15am ? 1:00pm Eastern Time

Session Title: Stem cells/gene therapy/transplantation/laser/local therapy

Format: Poster Presentation

Presenter: John Dodd, PhD, Senior Vice President of Preclinical Research

"Protective Effects of 2 Melanocortin Agonists DeliveredTitle: by Intravitreal Injection in Mouse Models of Retinopathy"